Iridex Stock Price, News & Analysis

Iridex Corporation (NASDAQ: IRIX) announced the enrollment of the first patient in the independent DAME Trial, evaluating the combination of MicroPulse technology with anti-VEGF therapy for severe diabetic macular edema (DME). The UK-based study, led by Professor Noemi Lois at Queen's University Belfast, aims to enroll 264 participants across 20 clinical sites.

The trial will assess the clinical efficacy, safety, cost-effectiveness, and patient acceptability of adding subthreshold MicroPulse treatments to anti-VEGF therapy. The study focuses on patients with severe DME, defined by central retinal subfield thickness ≥400 μm. The research is funded by the National Institute for Health Research (NIHR) and utilizes Iridex's IQ 577® laser system with MicroPulse® treatment mode and TxCell® Scanning Delivery Device.

Iridex Corporation (IRIX) reported its Q1 2025 financial results, showing modest growth and operational improvements. Total revenue reached $11.9 million, up slightly from $11.8 million in Q1 2024. The Cyclo G6 product family revenue increased 8% year-over-year to $3.2 million, with 13,900 probes and 24 Glaucoma Laser Systems sold. Retina product revenue declined 3% to $6.6 million. Notable improvements include a 32% reduction in operating expenses and positive adjusted EBITDA of $0.4 million, compared to a $2.5 million loss last year. The company strengthened its balance sheet through a $10 million strategic investment from Novel Inspiration. Gross margin improved to 42.5% from 37.9% in Q1 2024. Net loss decreased to $1.7 million ($0.10 per share) from $3.5 million ($0.21 per share) year-over-year. The company aims to achieve cash flow breakeven and maintain positive adjusted EBITDA in 2025.

Iridex Corporation (Nasdaq: IRIX), a leader in laser-based medical systems for treating glaucoma and retinal diseases, has scheduled its first quarter 2025 financial results announcement for May 13, 2025, after market close.

The company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET on the same day. Investors can join the call by dialing +1-888-596-4144 with conference ID: 698002.

A live and recorded webcast of the event will be accessible through the "Event Calendar" page in the "Investors" section of Iridex's website at www.iridex.com.

Iridex (NASDAQ:IRIX) has released preliminary Q1 2025 financial results, showing signs of business stabilization. The company expects total revenue between $11.8-12.0 million, comparable to Q1 2024's $11.8 million.

Key operational metrics include sales of approximately 13,900 Cyclo G6 probes (up from 13,300 year-over-year) and 24 Cyclo G6 Laser Systems (up from 22). Cash and cash equivalents stood at $7.2 million as of March 29, 2025.

The company reports improved financial condition following strategic investment from Novel Inspiration International Co., , with consecutive quarterly revenue increases while reducing operating expenses. Management indicates potential for breakeven or better performance at historical revenue levels, despite exposure to external factors like tariff policy changes.

Iridex (Nasdaq: IRIX), a leading provider of laser-based medical systems for glaucoma and retinal diseases, has announced a strategic vision call scheduled for April 16, 2025. The call will outline the company's strategic direction following Novel's recent strategic investment.

The conference call is set to begin at 2:00 p.m. PT / 5:00 p.m. ET. Investors can participate by dialing 888-596-4144 with conference ID: 9584140. Both a live and recorded webcast will be accessible through the 'Event Calendar' section on Iridex's investor relations website.

Iridex (IRIX) reported its Q4 and full year 2024 financial results, highlighting positive adjusted EBITDA in Q4 2024. The company generated Q4 revenue of $12.7 million, up from $12.5 million year-over-year, while implementing cost reductions that decreased operating expenses by 24% to $6.1 million.

Key Q4 metrics include Cyclo G6® product revenue of $3.3 million and Retina product revenue of $7.3 million. The company's net loss improved to $0.8 million from $3.0 million in the prior year quarter. For full year 2024, total revenue was $48.7 million, down from $51.9 million in 2023.

Notably, Iridex secured a strategic investment of $10 million at $2.00 per share, with an option for an additional $10 million for future growth. The company expects to achieve cash flow breakeven and positive adjusted EBITDA in 2025 on revenue consistent with 2024 levels.

Iridex (NASDAQ: IRIX) has secured a strategic investment of $10 million from Novel Inspiration International Co., , with an option for an additional $10 million for future growth initiatives. The initial transaction includes $6 million in new Series B Preferred Stock and $4 million in convertible notes, both priced at $2.00 per share equivalent.

The convertible notes have a three-year term with 12% interest, payable quarterly in common stock. Novel has the right to appoint two board members, with William Moore, former CEO and board member, joining the board. The funding will be used to repay existing debt and for general corporate purposes.

The company also announced the appointment of Romeo Dizon as CFO, replacing Interim CFO Fuad Ahmad. This strategic investment aims to enhance Iridex's ability to pursue opportunities in advanced laser-based treatments, particularly following the November 2024 LCD that introduced new limitations for MIGS devices.

Iridex (NASDAQ: IRIX), a provider of laser-based medical systems for glaucoma and retinal diseases treatment, has addressed recent stock price volatility observed on March 13, 2025. The company explicitly stated there are no material developments or changes to its operating or financial condition that would explain the recent price and volume movements.

The company confirmed that no material adverse changes have occurred to its operating results, business, strategy, or prospects since their preliminary Q4 and full year 2024 results announcement on January 14, 2025. Final financial results will be discussed during a conference call scheduled for March 27, 2025, at 2:00pm PT.

Iridex (NASDAQ: IRIX), a provider of laser-based medical systems for glaucoma and retinal diseases treatment, has scheduled its Fourth Quarter and Full Year 2024 financial results announcement for March 27, 2025, after market close.

The company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET on the same day. Investors can join via phone at +1-888-596-4144 (Conference ID: 5685253) or access the webcast through the Event Calendar on Iridex's investor relations website.